Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Mod Pathol. 2019 Apr 17;32(9):1344–1358. doi: 10.1038/s41379-019-0269-x

Table 3.

9p24.1 Amplified Renal Cell Carcinomas: 9p24.1 Amplification Status

Case Identifier DNA Assay: 9p24.1 Amplification (Next Generation Sequencing) DNA Assay: 9p24.1 Amplification (fluorescence in situ hybridization) RNA Assay: (RNASeq Protein Assay: (p-STAT3 IHC, H-Scores Protein Assay: (PD-L1 IHC, H-Scores Protein Assay: (PD-L2 IHC, H-Scores Protein Assay: (PD1 IHC
Case 1 (Discovery Cohort) JAK2: 3.5-fold change
PD-L1: 3.5-fold change
PD-L2: 3.5-fold change		 JAK2/INSL6: + - p-STAT3: 210 PD-L1: 240 PD-L2: 200 PD1: +++
Case 2 (Discovery Cohort) JAK2: 3.3-fold change
PD-L1: 3.1-fold change
PD-L2: not tested		 JAK2/INSL6: + - p-STAT3: 170 PD-L1: 180 PD-L2: 0 PD1: +
Case 3 (Discovery Cohort & Casuscelli et al) JAK2: 3.1-fold change
PD-L1: 3.1-fold change
PD-L2: not tested		 JAK2/INSL6: + - p-STAT3: 0 PD-L1: 220 PD-L2: 40 PD1: +
Case 4 (Discovery Cohort) JAK2: 2.7-fold change
PD-L1: 2.7-fold change
PD-L2: 2.7-fold change		 JAK2/INSL6: +
PD-L1/PD-L2: +		 - p-STAT3: 10 PD-L1: 270 PD-L2: 10 PD1: +
Case 5 (Discovery Cohort) JAK2: 1.9-fold change
PD-L1: 1.9-fold change
PD-L2: not tested		 JAK2/INSL6: + - p-STAT3: 100 PD-L1: 260 PD-L2: 10 PD1: 0
Case 6 (TCGA-BP-4983) JAK2/PD-L1/PD-L2 amplified JAK2/INSL6: +
PD-L1/PD-L2: +		 JAK2/PD-L1: 100th percentile PD-L2: 99th percentile p-STAT3: 30 PD-L1: 290 PD-L2: 0 PD1: +
Case 7 (Validation Cohort) - JAK2/INSL6: +
PD-L1/PD-L2: +		 - - PD-L1: 290 PD-L2: 0 -
Case 8 (Validation Cohort) - JAK2/INSL6: + - - PD-L1: 245 PD-L2: 5 -
Case 9 (Validation Cohort) - JAK2/INSL6: + - - PD-L1: 140 PD-L2: 0 -
Case 10 (Validation Cohort) - JAK2/INSL6: + - - PD-L1: 85 PD-L2: 0 -
Case 11 (TCGA-CZ-5468) JAK2/PD-L1/PD-L2 amplified - JAK2/PD-L1: 73rd–78th percentile PD-L2: 94th percentile - - - -
Case 12 (TCGA-B8-4143) JAK2 amplified - JAK2: 72nd percentile - - - -
Case 13 (Casuscelli et al) PD-L1 amplified - - - - - -

TCGA: The Cancer Genome Atlas; IHC: immunohistochemistry.